Abstract

CORE B The Biochemistry Core will provide the entire group with expertise in peptide chemistry and chromatographic separations: The core will: 1) synthesize and purify economically peptides for the research projects; 2) help with HPLC purification of peptides extracted from cells as putative tumor antigens; 3) give the group access to long-term expertise to adjust procedures and protocols rapidly and effectively depending on the individual properties of peptides and proteins and the requirements for use of peptides and proteins in culture and in vivo. Directing its operation will be the responsibility of Dr. Meredith. It will be staffed by an experienced technician, Ms. Auer. The core will be located on the 6th floor of the AMB building of the University of Chicago, next to Dr. Meredith's main laboratory. Integration of the Biochemistry Core into the program will be the responsibility of the Program Director.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA074182-04
Application #
6481884
Study Section
Project Start
2001-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost

  Institution

Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637

  Publications

Binder, David C; Schreiber, Hans (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res 74:632; discussion 635
Arina, Ainhoa; Schreiber, Karin; Binder, David C et al. (2014) Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 192:1286-93
Schreiber, Karin; Arina, Ainhoa; Engels, Boris et al. (2012) Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 18:2526-33
Wu, Terry H; Schreiber, Karin; Arina, Ainhoa et al. (2011) Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun 11:2
Gidalevitz, Tali; Biswas, Chhanda; Ding, Hua et al. (2004) Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J Biol Chem 279:16543-52
Eiben, Gretchen L; Velders, Markwin P; Kast, W Martin (2002) The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res 86:113-48
Salit, Rachel B; Kast, W Martin; Velders, Markwin P (2002) Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 7:e204-13
Wakabayashi, Mark T; Da Silva, Diane M; Potkul, Ronald K et al. (2002) Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 45:300-7
Schreiber, H; Wu, T H; Nachman, J et al. (2002) Immunodominance and tumor escape. Semin Cancer Biol 12:25-31
Vogen, Shawn; Gidalevitz, Tali; Biswas, Chhanda et al. (2002) Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J Biol Chem 277:40742-50

Showing the most recent 10 out of 35 publications